Table 1.
Characteristics of included studies of glucocorticoids in cardiac arrest
| Study details | Mentzelopoulos et al. [28] | Mentzelopoulos et al. [27] | Andersen et al. [26] |
|---|---|---|---|
| Country | Greece | Greece | Denmark |
| Period of enrollment | 2005 to 2006 | 2008 to 2010 | 2018 to 2021 |
| Type of population | |||
| In-hospital | ✓ | ✓ | ✓ |
| Sample size, N | 100 | 268 | 501 |
| Cases for analysis, N | |||
| VSE group | 48 | 130 | 237 |
| Control group | 52 | 138 | 264 |
| Age, y | |||
| VSE group | 65.5 ± 17.7 | 63.2 ± 17.6 | 71.0 ± 13.0 |
| Control group | 69.2 ± 17.7 | 62.8 ± 18.6 | 70.0 ± 12.0 |
| Male gender, % | |||
| VSE group | 63 | 73.1 | 62 |
| Control group | 56 | 63.8 | 66 |
| Study design | |||
| Prospective RCTs | ✓ | ✓ | ✓ |
| Inclusion and exclusion criteria defined | ✓ | ✓ | ✓ |
| Excluded patients specified | ✓ | ✓ | ✓ |
| Relevant baseline characteristics | ✓ | ✓ | ✓ |
| Reporting | |||
| ROSC | ✓ | ✓ | ✓ |
| Survival | ✓ | ✓ | ✓ |
| MAP during and after CPR | ✓ | ✓ | |
| Ventilator free days | ✓ | ✓ | ✓ |
| Organ failure free days | ✓ | ✓ | |
| Complication and Adverse events | ✓ | ✓ | ✓ |
| Neurologic Outcome | ✓ | ✓ | ✓ |
Values are mean ± SD where appropriate
N number, VSE vasopressin, steroid, and epinephrine, RCTs randomized clinical trials, ROSC return of spontaneous circulation, MAP mean arterial pressure, CPR cardiopulmonary resuscitation